Principles for consistent value assessment and sustainable funding of orphan drugs in Europe

The European Orphan Medicinal Products (OMP) Regulation has successfully encouraged research to develop treatments for rare diseases resulting in the authorisation of new OMPs in Europe. While decisions on OMP designation and marketing authorisation are made at the European Union level, reimbursemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierrez, Laura, Patris, Julien, Hutchings, Adam, Cowell, Warren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433088/
https://www.ncbi.nlm.nih.gov/pubmed/25935555
http://dx.doi.org/10.1186/s13023-015-0269-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433088/
https://www.ncbi.nlm.nih.gov/pubmed/25935555
http://dx.doi.org/10.1186/s13023-015-0269-y

Ejemplares similares